EyePoint (EYPT) Q1 2026 earnings summary

Executive summary

• DURAVYU, leveraging proprietary Durasert E technology, is advancing through pivotal Phase 3 trials in wet AMD (LUGANO, LUCIA) and DME (COMO, CAPRI), with topline data for wet AMD expected mid-2026 and DME enrollment completion in Q3 2026.

• DURAVYU is positioned as a potential first-to-market, best-in-class sustained-release therapy for retinal diseases, supported by robust clinical data and a unique multi-mechanism of action.

• Commercial readiness activities, organizational expansion, and appointment of a new Chief Commercial Officer are underway to support anticipated regulatory submission and launch.

• Legal action was initiated against Ocular Therapeutix for alleged defamation and commercial disparagement regarding DURAVYU.

• Agreement in principle reached with DOJ and HHS to settle an investigation for $4.9 million, pending final documentation.

Financial highlights

• Ended Q1 2026 with $223 million in cash and investments, expected to fund operations into Q4 2027.

• Q1 2026 net revenue was $0.7 million, down from $24.5 million in Q1 2025 due to prior deferred revenue recognition from licensing agreements.

• Operating expenses rose to $88 million from $73 million year-over-year, driven by Phase 3 trials and manufacturing scale-up.

• Net loss widened to $85 million ($0.99/share) from $45 million ($0.65/share) in the prior year.

• R&D expenses rose 23% to $72.1 million, with DURAVYU direct R&D expense at $46.9 million in Q1 2026.

Outlook and guidance

• Cash and investments expected to fund operations into Q4 2027, beyond anticipated Phase 3 topline data for DURAVYU.

• Topline data from Phase 3 LUGANO trial in wet AMD expected mid-2026, with LUCIA to follow; DME topline data anticipated in H2 2027.

• Full enrollment for both pivotal DME trials targeted for Q3 2026.

• Continued significant operating losses expected as clinical development and regulatory activities progress.

• Additional funding may be sought depending on trial outcomes, regulatory developments, and business needs.